Alivus Life Sciences Records Highest-Ever PAT, Driven by Strong Non-GPL Growth and 36.6% EBITDA Margins in Q1FY27
Mumbai: Alivus Life Sciences Limited, a developer and manufacturer of high-value Active Pharmaceutical Ingredients (APIs) for chronic therapeutic areas, announced strong financial results for the quarter ended June 30, 2026. The company reported its highest-ever PAT (Profit After Tax), supported by robust growth in its non-GPL business segment.The company saw revenue from operations reach Rs. 6,404 Mn for Q1FY27, marking a 6.4% year-over-year growth. EBITDA stood at Rs. 2,341 Mn, reflecting a 29.1% YoY increase and achieving margins of 36.6%. PAT reached Rs. 1,601 Mn, a rise of 31.8% YoY.
The financial performance for Q1FY27 is detailed below:
| Metric | Value (Q1FY27) | Year-over-Year Growth |
|---|---|---|
| Revenue from Operations | Rs. 6,404 Mn | 6.4% |
| EBITDA | Rs. 2,341 Mn | 29.1% |
| PAT | Rs. 1,601 Mn | 31.8% |
| PAT Margin | 25.0% | Up 480 bps |
Alivus generated a free cash flow of Rs. 901 Mn during the quarter. As of June 30, 2026, the company held Cash and Cash Equivalents (including short-term investments) amounting to Rs. 8,802 Mn.
Strategic Performance and Outlook
Dr. Yasir Rawjee, MD and CEO of Alivus Life Sciences Limited, commented on the performance, noting that the results demonstrate the resilience and strong execution of the company's business model. He highlighted the accelerating traction in the non-GPL business, which saw a 26.5% YoY growth.Dr. Rawjee stated that while the GPL business is expected to be flattish in FY27 due to a significant decline observed in Q1FY27—a trend consistent with historical trends for this segment—the company remains confident of achieving revenue growth between 10% and 12% in FY27. Management expects to sustain EBITDA margins in the 30% to 32% range as ongoing investments strengthen the foundation for future expansion.
Tushar Mistry, CFO of Alivus Life Sciences Limited, noted that the results reflected a strong portfolio and disciplined execution, driving profitability through operating leverage and successful new product launches. He emphasized that the company remains net debt-free, noting that the substantial cash reserves provide flexibility for investment in future growth while creating long term value.
Operations and Future Capacity Expansion
The company continues to expand its operational capabilities and pipeline development. As of June 30, 2026, the cumulative DMF / CEP filings across major markets totaled 617.Regarding portfolio strength, the HP API portfolio comprises 29 APIs in the active grid. Of these, 13 products are validated, seven products are in advanced stages of development, and nine products are progressing through lab development.
Alivus is also advancing significant capital expenditure projects to bolster future capacity. Construction work for Phase 1 (350 KL capacity) and Phase 2 (115 KL capacity) at the Solapur facility is currently underway, with completion anticipated in Q3 FY27 and Q4 FY27, respectively. Furthermore, construction has begun on a new R&D facility in Taloja (Navi Mumbai), which will be dedicated to advanced areas including flow chemistry, complex products, particle engineering, oncology research, and green chemistry.
ALIVUS Stock Price Movement
Shares of Alivus Life Sciences Limited settled today, shedding 0.41% to close at ₹1095.7. The stock traded within an intraday range marked by a high of ₹1142.9 and a low of ₹1089.8, with total volume reaching 53,239 shares.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.
Last edited by a moderator: